Highlights Akeso, Inc.

Equities

9926

KYG0146B1032

Market Closed - Hong Kong S.E. Other stock markets 09:08:20 14/05/2024 BST			5-day change	1st Jan Change
49.2 ^HKD	-0.10%		+0.41%	+6.03%

04-24	Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator	MT
04-24	National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer	04-24	CI
Akeso to Raise Over HK$1 Billion Via Share Sale	03-22	MT
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast	03-19	MT
Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18	CI
Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC	03-06	CI
Akeso Books First-Ever Profit in 2023; Shares Fall 5%	03-05	MT
Akeso, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	03-04	CI
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	02-15	RE
Akeso Unit Buys 35% Stake in Biopharmaceutical Firm from Dawnrays; Akeso Shares Slide 3%	02-09	MT
Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI	01-23	CI
Akeso, Inc. Announces Innovative Clinical Development Roadmap	01-08	CI
Chinese Medical Regulator Accepts Akeso’s Supplemental New Drug Application for Gastric Cancer Therapy	01-05	MT
Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer	01-05	CI
Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023	12-15	CI
Akeso Publishes Results from Three Investigator-Initiated Trials	12-05	CI
Akeso Launches Construction of Shanghai Global R&D Center to Accelerate its Innovation Globalization Strategy	11-28	CI
Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival for First-Line Treatment of Recurrent/Metastatic Cervical Cancer	11-27	CI
Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer	11-22	CI
Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)	11-07	CI
Akeso, Inc. Announces A Phase III Trial of Cadonilimab in Combination with Chemotherapy as First Line Treatment for GASTRIC or Gastesophageal Junction Adenocarcinoma (GC/GEJC) Reaches Primary Endpoint of Overall Survival	11-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Akeso, Inc.

Equities

9926

KYG0146B1032

Highlights

Filters